Currently, the biological hallmarks of CLL are well recognized as B-cell receptor and Bruton tyrosine kinase signaling (3), as well as resistance to apoptosis mediated by Bcl-2, which has revolutionized CLL clinical management. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.